Geode Capital Management LLC Has $79.03 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Geode Capital Management LLC boosted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 12.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,289,549 shares of the company's stock after acquiring an additional 482,177 shares during the quarter. Geode Capital Management LLC owned about 2.00% of Hims & Hers Health worth $79,029,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of HIMS. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the last quarter. Wellington Management Group LLP increased its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company's stock worth $10,663,000 after purchasing an additional 328,142 shares in the last quarter. State of Michigan Retirement System raised its holdings in Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company's stock worth $10,095,000 after buying an additional 320,000 shares during the period. Finally, Carnegie Investment Counsel purchased a new stake in Hims & Hers Health during the third quarter valued at about $5,531,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other news, COO Melissa Baird sold 58,750 shares of the company's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50. Following the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at approximately $12,332,348.62. This represents a 8.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 9,868 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $19.96, for a total value of $196,965.28. Following the completion of the transaction, the chief financial officer now directly owns 195,988 shares of the company's stock, valued at approximately $3,911,920.48. The trade was a 4.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,085,157 shares of company stock valued at $26,765,193 over the last ninety days. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded down $0.16 on Friday, hitting $26.20. 17,248,361 shares of the company were exchanged, compared to its average volume of 10,078,416. The company's 50 day moving average price is $25.78 and its two-hundred day moving average price is $21.27. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 59.55 and a beta of 1.25. Hims & Hers Health, Inc. has a one year low of $8.09 and a one year high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) EPS. The company's revenue for the quarter was up 77.1% on a year-over-year basis. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HIMS. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research report on Monday, December 2nd. TD Cowen reissued a "buy" rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus target price of $22.80.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.